Additionally, recent clinical data suggest that inhibiting the JAK-STAT signaling pathway may further enhance responses to checkpoint blockade in cHL, likely through modulation of PD-L1 expression and the inflammatory microenvironment within the TME. The gene discussed is CD274; the disease is classic Hodgkin lymphoma.